{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:44:45Z","timestamp":1794242685975,"version":"4.9.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ophtha.2025.12.022","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:19:44Z","timestamp":1767025184000},"page":"589-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6114-8629","authenticated-orcid":false,"given":"Zhengyang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-3849","authenticated-orcid":false,"given":"Dev","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-8324","authenticated-orcid":false,"given":"Spiros","family":"Fourlanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-4685","authenticated-orcid":false,"given":"Elaine W.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2025.12.022_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ophtha.2025.12.022_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.12.022_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsboll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.12.022_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ceo.13393","article-title":"Early worsening of diabetic retinopathy due to intensive glycaemic control","volume":"47","author":"Lim","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/diacare.23.8.1084","article-title":"Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group","volume":"23","author":"Diabetes","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2025.12.022_bib6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ophtha.2025.12.022_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib9","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.12.022_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Hattenhauer","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00041327-199403000-00011","article-title":"Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California","volume":"14","author":"Johnson","year":"1994","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib12","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1111\/dom.70013","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: a systematic review and meta-analysis of observational studies","volume":"27","author":"Goldenberg","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.12.022_bib13","article-title":"Semaglutide and non-arteritic anterior ischemic optic neuropathy: a systematic review","volume":"17","author":"Hidalgo Ramos","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.ophtha.2025.12.022_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular adverse events with semaglutide: a systematic review and meta-analysis","volume":"143","author":"Natividade","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.05.011","article-title":"Nonarteritic anterior ischemic optic neuropathy and glucagon-like peptide-1 receptor agonists: evaluating a potential association","volume":"140","author":"Ozbek","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ophtha.2025.12.022_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2025.12.022_bib18","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2025.12.022_bib19","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2025.12.022_bib20","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.12.022_bib21","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.12.022_bib22","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.12.022_bib23","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"385","author":"Wilding","year":"2021","journal-title":"Reply N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.12.022_bib24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.12.022_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib26","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2025.12.022_bib27","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2025.12.022_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"134","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.12.022_bib31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/112067210701700335","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy in adult Chinese: the Beijing Eye Study","volume":"17","author":"Xu","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/WNO.0000000000002102","article-title":"Reexamining the incidence of nonarteritic anterior ischemic optic neuropathy: a Rochester epidemiology project study","volume":"44","author":"Foster","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ophtha.2011.01.054","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients","volume":"118","author":"Lee","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.12.022_bib35","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.ophtha.2016.08.017","article-title":"Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Cestari","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.12.022_bib36","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: a large scale meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ophtha.2025.12.022_bib37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Frias","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaophthalmol.2024.2514","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"142","author":"Mollan","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib39","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/dom.15529","article-title":"Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression","volume":"26","author":"Rivera","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.12.022_bib40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hernandez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ophtha.2025.12.022_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ophtha.2024.01.011","article-title":"Ophthalmic and systemic factors of acute nonarteritic anterior ischemic optic neuropathy in the Quark207 treatment trial","volume":"131","author":"Kupersmith","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.12.022_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system - a disproportionality analysis","volume":"19","author":"Azab","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.ophtha.2025.12.022_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like Peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.12.022_bib45","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025008036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025008036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:11:21Z","timestamp":1792804281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025008036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0161642025008036"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.12.022","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}